Giant osteoclasts in patients under bisphosphonates.

作者: Fabrice Mac-Way , Andrea Trombetti , Christian Noel , Marie-Hélène Lafage-Proust , None

DOI: 10.1186/1472-6890-14-31

关键词:

摘要: Bisphosphonates have been widely used for treatment of high bone resorption states. It lowers turnover by inhibiting osteoclasts with various mechanisms actions: inhibition osteoclast formation and attachment to the surface, induction metabolic injury, alteration vesicle trafficking apoptosis. Bone biopsies studies from patients under bisphosphonates shown that some parameters are decreased as expected but number seems not be necessarily decreased. The description morphology treated has rarely reported in literature. We describe this paper two whom iliac crest large, multinucleated apoptotic were associated activities. characteristics these described literature reviewed. appropriate recognition giant tissues is primary importance pathologists should interpreted signs increased seen hyperparathyroidism, cancer or Paget’s disease bone.

参考文章(18)
A. Alakangas, K. Selander, M. Mulari, J. Halleen, P. Lehenkari, J. Mönkkönen, J. Salo, K. V n nen, Alendronate disturbs vesicular trafficking in osteoclasts. Calcified Tissue International. ,vol. 70, pp. 40- 47 ,(2002) , 10.1007/S002230010047
R Eastell, I Barton, Ra Hannon, A Chines, P Garnero, Pd Delmas, Relationship of Early Changes in Bone Resorption to the Reduction in Fracture Risk With Risedronate Journal of Bone and Mineral Research. ,vol. 18, pp. 1051- 1056 ,(2003) , 10.1359/JBMR.2003.18.6.1051
Nidhi Jain, Robert S. Weinstein, Giant osteoclasts after long-term bisphosphonate therapy: diagnostic challenges Nature Reviews Rheumatology. ,vol. 5, pp. 341- 346 ,(2009) , 10.1038/NRRHEUM.2009.87
Michael McClung, Bjorg Clemmesen, Anastasia Daifotis, Nigel L Gilchrist, John Eisman, Robert S Weinstein, Ghada El Hajj Fuleihan, Celia Reda, A John Yates, Pernille Ravn, Alendronate Prevents Postmenopausal Bone Loss in Women without Osteoporosis: A Double-Blind, Randomized, Controlled Trial Annals of Internal Medicine. ,vol. 128, pp. 253- 261 ,(1998) , 10.7326/0003-4819-128-4-199802150-00001
Michael J. Rogers, S. Gordon, H. L. Benford, F. P. Coxon, S. P. Luckman, J. Monkkonen, J. C. Frith, Cellular and molecular mechanisms of action of bisphosphonates Cancer. ,vol. 88, pp. 2961- 2978 ,(2000) , 10.1002/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.0.CO;2-L
P M Chavassieux, M E Arlot, C Reda, L Wei, A J Yates, P J Meunier, Histomorphometric Assessment of the Long-term Effects of Alendronate on Bone Quality and Remodeling in Patients with Osteoporosis Journal of Clinical Investigation. ,vol. 100, pp. 1475- 1480 ,(1997) , 10.1172/JCI119668
Clemens W.G.M. Löwik, G. Van Der Pluijm, L.J.A. Van Der Wee-Pals, H. Bloys Van Treslong-De Groot, O.L.M. Bijvoet, Migration and phenotypic transformation of osteoclast precursors into mature osteoclasts: The effect of a bisphosphonate Journal of Bone and Mineral Research. ,vol. 3, pp. 185- 192 ,(2009) , 10.1002/JBMR.5650030210
Robert S. Weinstein, Paula K. Roberson, Stavros C. Manolagas, Giant Osteoclast Formation and Long-Term Oral Bisphosphonate Therapy The New England Journal of Medicine. ,vol. 360, pp. 53- 62 ,(2009) , 10.1056/NEJMOA0802633